Design and X-ray Crystallographic Characterisation of Next-Generation Hydrazone Kinase Inhibitors for Breast Cancer Therapy

Authors

  • Karagiannis D Department of Medicinal Chemistry, National and Kapodistrian University of Athens, Athens, Greece Author
  • Kukk M Department of Structural Biology, University of Tartu, Tartu, Estonia Author
  • Gallagher C Department of Oncology, University College Dublin, Dublin, Ireland Author

DOI:

https://doi.org/10.5281/zenodo.22644014

Keywords:

hydrazone kinase inhibitors, breast cancer therapy, molecular docking, X-ray crystallography, structure-based drug design

Abstract

Background: Breast cancer remains the most frequently diagnosed malignancy in women worldwide, and its proliferation, survival,
and angiogenic signaling are driven by a well-characterized set of oncogenic protein kinases, including epidermal growth factor
receptor (EGFR), HER2, cyclin-dependent kinases (CDK2 and CDK4/6), the phosphoinositide 3-kinase/AKT/mTOR axis, and vascular
endothelial growth factor receptor 2 (VEGFR-2). The hydrazone functional group, a synthetically accessible and conformationally
rigid -C=N-NH- linkage, has been widely exploited to fuse hinge-binding heterocyclic fragments into next-generation
kinase-inhibitor chemotypes directed against these targets. Objective: This narrative review synthesizes the published literature on
hydrazone and hydrazone-hybrid kinase inhibitors designed, molecularly docked, and, where available, X-ray crystallographically
characterized for activity against breast cancer-relevant kinase targets. Methods: Peer-reviewed studies reporting the synthesis,
kinase-directed molecular docking, and single-crystal X-ray diffraction of hydrazone-based inhibitors targeting EGFR, HER2,
CDK2/CDK4-6, the PI3K/AKT/mTOR axis, or VEGFR-2 were identified, individually verified against their primary source records, and
synthesized thematically around pharmacophore rationale, docking outcomes, crystallographic validation, and structure-activity
relationships. Findings: Hydrazone-based series have been docked against EGFR, HER2, CDK2, PI3K/AKT effectors, VEGFR-2, and
Aurora B, with reported binding energies as favorable as -23.44 kcal/mol and potencies spanning sub-nanomolar enzymatic
inhibition to low-micromolar cytotoxicity against MCF-7 and MDA-MB-231 breast cancer cell lines, in several cases exceeding
doxorubicin or staurosporine reference standards. Experimental X-ray crystallography, though so far confined largely to
free-ligand solid-state structures rather than true protein-ligand co-crystal complexes, has confirmed the hydrazone bridge
geometry of several lead compounds, while the historical sunitinib-VEGFR2 and erlotinib-EGFR co-crystal structures continue to
provide the structural templates against which newly docked hydrazone poses are benchmarked. Conclusions: Hydrazone and
hydrazone-hybrid chemotypes constitute a chemically versatile and increasingly well-validated class of breast cancer
kinase-inhibitor candidates, and expanded application of experimental co-crystallography, including genuine protein-ligand
complexes, represents the most direct route to closing the persistent gap between computational docking prediction and
structurally confirmed binding modes in this field.

References

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(3):229-263, DOI:10.3322/caac.21834.

Stamos J, Sliwkowski MX, Eigenbrot C (2002) Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. Journal of Biological Chemistry, 277(48):46265-46272, DOI:10.1074/jbc.M207135200.

Li H, Prever L, Hirsch E, Gulluni F (2021) Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer. Cancers, 13(14):3517, DOI:10.3390/cancers13143517.

Avdicevic A, Lesnik S, Bren U, Cavka L (2026) CDK4/6 Inhibitors for Breast Cancer Therapy-A Review of Clinical Trials, Structural and Computational Approaches. Pharmaceuticals, 19(4):610, DOI:10.3390/ph19040610.

McTigue M, Murray BW, Chen JH, Deng YL, Solowiej J, Kania RS (2012) Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors. Proceedings of the National Academy of Sciences, 109(45):18281-18289, DOI:10.1073/pnas.1207759109.

Rollas S, Kucukguzel SG (2007) Biological Activities of Hydrazone Derivatives. Molecules, 12(8):1910-1939, DOI:10.3390/12081910.

Salama EE, Youssef MF, Aboelmagd A, Boraei ATA, Nafie MS, Haukka M, Barakat A, Sarhan AAM (2023) Discovery of Potent Indolyl-Hydrazones as Kinase Inhibitors for Breast Cancer: Synthesis, X-ray Single-Crystal Analysis, and In Vitro and In Vivo Anti-Cancer Activity Evaluation. Pharmaceuticals, 16(12):1724, DOI:10.3390/ph16121724.

Al-Warhi T, Almahli H, Maklad RM, Elsayed ZM, El Hassab MA, Alotaibi OJ, Aljaeed N, Ayyad RR, Ghabour HA, Eldehna WM, El-Ashrey MK (2023) 1-Benzyl-5-bromo-3-hydrazonoindolin-2-ones as Novel Anticancer Agents: Synthesis, Biological Evaluation and Molecular Modeling Insights. Molecules, 28(7):3203, DOI:10.3390/molecules28073203.

Al-Sanea MM, Obaidullah AJ, Shaker ME, Chilingaryan G, Alanazi MM, Alsaif NA, Alkahtani HM, Alsubaie SA, Abdelgawad MA (2021) A New CDK2 Inhibitor with 3-Hydrazonoindolin-2-One Scaffold Endowed with Anti-Breast Cancer Activity: Design, Synthesis, Biological Evaluation, and In Silico Insights. Molecules, 26(2):412, DOI:10.3390/molecules26020412.

Al-Salem HS, Arifuzzaman M, Alkahtani HM, Abdalla AN, Issa IS, Alqathama A, Albalawi FS, Rahman AFMM (2020) A Series of Isatin-Hydrazones with Cytotoxic Activity and CDK2 Kinase Inhibitory Activity: A Potential Type II ATP Competitive Inhibitor. Molecules, 25(19):4400, DOI:10.3390/molecules25194400.

Albalawi FS, Bhat MA, Bakheit AH, Rahman AFMM, Alsaif NA, Jones AM, Romero-Canelon I (2025) Purine-Hydrazone Scaffolds as Potential Dual EGFR/HER2 Inhibitors. Pharmaceuticals, 18(7):1051, DOI:10.3390/ph18071051.

Salama EE, Althobaiti IO, Haukka M, Boraei ATA (2022) Synthesis, X-ray Single-Crystal Analysis, and Anticancer Activity Evaluation of New Alkylsulfanyl-Pyridazino[4,5-b]indole Compounds as Multitarget Inhibitors of EGFR and Its Downstream PI3K-AKT Pathway. Crystals, 12(3):353, DOI:10.3390/cryst12030353.

Sermuksnyte A, Kantminiene K, Jonuskiene I, Tumosiene I, Petrikaite V (2022) The Effect of 1,2,4-Triazole-3-thiol Derivatives Bearing Hydrazone Moiety on Cancer Cell Migration and Growth of Melanoma, Breast, and Pancreatic Cancer Spheroids. Pharmaceuticals, 15(8):1026, DOI:10.3390/ph15081026.

Sermuksnyte A, Stasevych M, Komarovska-Porokhnyavets O, Zvarych V, Jakubauskiene E, Kantminiene K, Tumosiene I (2024) Novel Antimicrobial and Antitumor Agents Bearing Pyridine-1,2,4-triazole-3-thione-hydrazone Scaffold: Synthesis, Biological Evaluation, and Molecular Docking Investigation. Biomolecules, 14(12):1529, DOI:10.3390/biom14121529.

Dilek O (2025) Comprehensive study of imidazole-based hydrazones: From design, synthesis, and characterization to in vitro and in silico antiproliferative activity analysis. Turkish Journal of Chemistry, 49(4):419-438, DOI:10.55730/1300-0527.3741.

Aydin E, Senturk AM, Kucuk HB, Guzel M (2022) Cytotoxic Activity and Docking Studies of 2-arenoxybenzaldehyde N-acyl Hydrazone and 1,3,4-Oxadiazole Derivatives against Various Cancer Cell Lines. Molecules, 27(21):7309, DOI:10.3390/molecules27217309.

Abdelgawad MA, Hayallah AM, Bukhari SNA, Musa A, Elmowafy M, Abdel-Rahman HM, Abd El-Gaber MK (2022) Design, Synthesis, Molecular Modeling, and Anticancer Evaluation of New VEGFR-2 Inhibitors Based on the Indolin-2-One Scaffold. Pharmaceuticals, 15(11):1416, DOI:10.3390/ph15111416.

Salama EE, Alrayes AA, Alrashdi S, Boraei ATA, Ahmed NI, Eid S, El-Nasser KS, Kalil H, Sarhan AAM (2026) Exploration of Novel Indole Compounds with Potential Activity Against Breast Cancer: Synthesis, Characterization and Anti-Cancer Activity Evaluation. Pharmaceuticals, 19(3):418, DOI:10.3390/ph19030418.

Hassan EM, Soliman SM, Moneer EA, Hagar M, Barakat A, Haukka M, Rasheed H (2023) Synthesis, X-ray Structure, Hirshfeld, DFT Conformational, Cytotoxic, and Anti-Toxoplasma Studies of New Indole-Hydrazone Derivatives. International Journal of Molecular Sciences, 24(17):13251, DOI:10.3390/ijms241713251.

Xie B, Shi M, Tang D, Yang S, Zeng Y, Nie L, Niu C (2026) Design and synthesis of novel indolinone Aurora B kinase inhibitors based on fragment-based drug discovery (FBDD). Molecular Diversity, 30(3):4015-4030, DOI:10.1007/s11030-025-11353-w.

Downloads

Published

2026-06-23